Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Maurie Markman, MD

November 23, 2021

Updated guidelines from the National Comprehensive Cancer Network list HER2 mutations as an emerging biomarker for targeted therapy with antibody drug conjugates (specifically, ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki). Access the full guidelines here.

Learn more about NSCLC treatment.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

Return to Article

Post as: